Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 41-47

  Matsuura, Motoki ^a   Suzuki, Takahiro ^a   Suzuki, Miwa ^a   Tanaka, Ryoichi ^a   Ito, Eiki ^a   Saito, Tsuyoshi ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Osteopontin; Ovarian clear cell carcinoma; Statin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; OSTEOPONTIN; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL CYCLE ARREST; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR XENOGRAFT;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN SITU NICK-END LABELING; MICE; OSTEOPONTIN; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650721441     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001039     Document Type: Article

References (40)

1. Giachelli CM and Steitz S: Osteopontin: a versatile regular of inflammation and biomineralization. Matrix Biol 19: 615-622, 2000.
2. Denhardt DT, Noda M, O'Regan AW, Pavlin D and Berman JS: Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-1061, 2001.
3. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R and Hughes J: Osteopontin -a molecule for all seasons. QJM 95: 3-13, 2002
4. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M and Rudland PS: The regulation and role of Osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 17: 463-474, 2006.
5. Chakraborty G, Jain S, Behera R, et al: The multifaceted roles of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830, 2006.
6. Philip S, Bulbule A and Kundu GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-?B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 276: 44926-44935, 2001
7. Tammela J, Geisler JP, Eskew PN Jr and Geisler HE: Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol 19: 438-440, 1998.
8. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 13: 1671-1679, 2002.
9. Nakae M, Iwamoto I, Fujino T, et al: Preoperative plasma Osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res 32: 309-314, 2006.
10. Lu KH, Patterson AP, Wang L, et al: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10: 3291-3300, 2004.
11. Kato N and Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1 beta expression. Histopathology 52: 682-688, 2008.
12. Matsuura M, Suzuki T and Saito T: Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci 101: 1828-1833, 2010.
13. Havel RJ and Rapaport E: Management of primary hyperlipidemia. N Eng J Med 332: 1301-1307, 1995.
14. Khaidakov M, Wang W, Khan JA, Kang BY, Hermonat PL and Mehta JL: Statins and angiogenesis: Is it about connections? Biochem Biophys Res Commun 387: 543-547, 2009.
15. Gauthaman K, Manasi N and Bongso A: Statins inhibit the growth of variant human embryonic stem cells and cancer cells in vitro but not normal human embryonic stem cells. Br J Pharmacol 157: 962-973, 2009.
16. Kwak B, Mulhaupt F, Myit S and Mach F: Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402, 2000.
17. Wong WW, Dimitroulakos J, Minden MD and Penn LZ: HMGCoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16: 508-519, 2002.
18. Minoretti P, Falcone C, Calcagnino M, et al: Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 27: 802-807, 2006.
19. Takemoto M, Kitahara M, Yokote K, et al: NK-104, a 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Br J Pharmacol 133: 83-88, 2001.
20. Heid CA, Stevens J, Livak KJ and Williams PM: Real-time quantitative PCR. Genome Res 6: 986-994, 1996.
21. Kon S, Maeda M, Segawa T, et al: Antibodies to different peptides in Osteopontin reveal complexities in the various secreted forms. J Cell Biochem 77: 487-498, 2000.
22. Johnson GA, Burghardt RC, Spencer TE, Newton GR, Ott TL and Bazer FW: Ovine Osteopontin: Osteopontin and alpha v beta 3 integrin expression in the uterus and conceptus during the periimplantation period. Biol Reprod 61: 892-899, 1999.
23. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
24. Coppola D, Szabo M, Boulware D, et al: Correlation of Osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190, 2004.
25. Khan SA, Lopez-chua CA, Zhang J, Fisher LW, Sorensen ES and Denhardt DT: Solube osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728-736, 2002.
26. Denhardt DT and Guo X: Osteopontin: a new protein with diverse functions. FASEB J 7: 1475-1482, 1993.
27. Hoque A, Chen H and Xu XC: Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 17: 88-94, 2008.
28. Maksimova E, Yie T and Rom WN: In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung 186: 45-54, 2008.
29. Gbelcova H, Lenicek M, Zelenka J, et al: Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 122: 1214-1221, 2008.
30. Glynn SA, Sullivan DO, Eustace AJ, Clynes M and Donovan NO: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 8: 9, 2008
31. Koyuturk M, Ersoz M and Altiok N: Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett 37: 212-217, 2004.
32. Jackobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
33. Lee J, Lee I, Park C and Kang WK: Lovastatin-induced Rho A modulation and its effect on senescence in prostate-cancer cells. Biochem Biophys Res Commun 339: 748-754, 2006.
34. Shibata MA, Kavanaugh C, Shibata E, et al: Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24: 453-459, 2003.
35. Horiguchi A, Sumitomo M, Asakura J, Asano T and Hayakawa M: 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10: 8648-8655, 2004.
36. Johnston NIF, Gunasekharan VK, Ravindranath A, O'Connel C, Johnston PG and EI-Tanani MK: Osteopontin as a target for cancer therapy. Front Biosci 13: 4361-4372, 2008
37. Elgavish A, Prince C, Chang PL, Lloyd K, Lindsey R and Reed R: Osteopontin stimulates a subpopulation of quiescent human prostate epithelial cells with high proliferative potential to divide in vitro. Prostate 35: 83-94, 1998.
38. Najib NM, Idkaidek N, Adel A, et al: Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (simvast and zocor) in healthy human volunteers. Biopharm Drug Dispos 24: 183-189, 2003. (Pubitemid 36939689)
39. Spek EVD, Bloem AC, Donk NWCJ, et al: Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haemtologica 91: 542-545, 2006.
40. Dimitroulakos J, Nohynek D, Backway KL, et al: Increased sensitivity of acute myeloid leukemias to Lovastatin induced apoptosis: A potential therapeutic approach. Blood 93: 1308-1318, 1999.